Thomas Eissing

Kaiser Wilhelm Allee
Leverkusen, NW 51373, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).

Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).

Journal: Lancet (London, England)

Published: April 23, 2026

Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products.

Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products.

Journal: CPT: pharmacometrics & systems pharmacology

Published: February 19, 2026

Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist.

Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist.

Journal: Eye (London, England)

Published: September 09, 2025

Impact of Event-Related Treatment Modifications in Exposure-Response Analyses of Repeated Time-to-Event Data.

Impact of Event-Related Treatment Modifications in Exposure-Response Analyses of Repeated Time-to-Event Data.

Journal: CPT: pharmacometrics & systems pharmacology

Published: July 07, 2025

Correction: Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study.

Correction: Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study.

Journal: Eye (London, England)

Published: February 09, 2024

NT-proBNP for Predicting All-Cause Death and Heart Transplant in Children and Adults with Heart Failure.

NT-proBNP for Predicting All-Cause Death and Heart Transplant in Children and Adults with Heart Failure.

Journal: Pediatric cardiology

Published: January 30, 2024

Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study.

Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study.

Journal: Eye (London, England)

Published: October 16, 2023

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone.

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone.

Journal: Clinical pharmacokinetics

Published: September 20, 2023

Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.

Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.

Journal: Diabetes, obesity & metabolism

Published: September 06, 2023

Evaluating Kidney Function Decline in Children with Chronic Kidney Disease Using a Multi-Institutional Electronic Health Record Database.

Evaluating Kidney Function Decline in Children with Chronic Kidney Disease Using a Multi-Institutional Electronic Health Record Database.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: May 13, 2022

Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD.

Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD.

Journal: Clinical pharmacokinetics

Published: March 24, 2022

Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.

Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.

Journal: Clinical pharmacokinetics

Published: October 08, 2021

Showing 1-12 of 51

Last Updated: 09/26/2026